))
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC
Manage episode 449104815 series 3560609
内容由Jacqueline Stone and Oncololgy News Central提供。所有播客内容（包括剧集、图形和播客描述）均由 Jacqueline Stone and Oncololgy News Central 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer Center in Los Angeles. Recent approvals by the U.S. Food and Drug Administration have introduced several “new friends,” in the form of amivantamab (Rybrevant) and lazertinib (Lazcluze). Dr. Sankar talks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology also at Cedars-Sinai Cancer Center, about how to choose among osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab plus lazertinib. Without overall survival data available for all choices, Dr. Sankar explains how she and her patients decide which treatment is best, as well as how to consider sequential therapy after disease progression.
Dr. Sankar reported no relevant financial relationships.
Dr. Figlin reported various financial relationships.
131集单集
分享
